The era of simply saying “Just Say No” appears to have faded.
Recently, President Trump enacted an executive order aimed at broadening the use of certain psychedelics for mental health treatment. This directive allocates $50 million and instructs the Food and Drug Administration to expedite the approval process. During the event, attended by administration officials, a former Navy SEAL, and podcaster Joe Rogan, the president humorously asked, “Can I have some, please?”
Later, the Trump administration declared that medical marijuana had been reclassified to a lower level on the controlled substances list, and urged the Drug Enforcement Administration to consider a similar move for recreational marijuana.
This shift in the administration’s stance on certain psychoactive substances signals a new direction in conservative drug policy. While the administration has maintained a strict, forceful approach towards fentanyl, its recent decisions on less potent drugs may mark the beginning of a significant change not only for Republican politics but also for the broader landscape of U.S. drug policy.
Kevin Sabet, CEO of Smart Approaches to Marijuana, an anti-legalization advocacy organization, expressed concern, stating, “With this imminent move, we are now confronted with the most pro-drug administration in our history.” He further criticized the influence of marijuana industry executives, psychedelic investors, and media figures, likening the marijuana sector to Big Tobacco and accusing the president of welcoming these industries into American homes.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
